What if everyone could get a test?

The earlier cancer is detected, the easier it is to fight. Knowing your risk early means knowing you’ll be alright.

Anpac Bio was founded in 2010 by a diverse team with backgrounds in medicine and biotechnology. Since beginning our cancer screening service in China in 2015, we have established blood databases with over 200,000 samples.

A cross disciplinary team.

Cancer Research & Detection

Chemistry & Bio-chemistry

Nano-technology & Physics

Surface & Material Science

Engineering & Manufacturing

It all started with professionals in medicine, nanotechnology, and engineering wondering the same question, What if we could detect cancer before tumors start?

Co-Founders Dr. Chris Yu and Dr. Herbert Yu brought together an integrated R&D team from China and the U.S. and tasked them with combining their expertise in mechatronics, physics, biomedical science and computer science to create our innovative, patented early cancer screening and detection technology.

210 patent applications filed globally with 128 patent applications granted.*

Our patented Cancer Differentiation Analysis (CDA) technology requires only a standard blood sample from a tested individual to conduct an early cancer screening and detection test, with no harmful side effects in patients.

*As of June 30, 2020

“game changing”

Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

©2019 Anpac Bio-Medical Science Co., Ltd.